ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,751,255 | -1.3% | 1,648,904 | +11.7% | 0.01% | 0.0% |
| Q2 2023 | $45,359,606 | -10.6% | 1,475,589 | +4.8% | 0.01% | -13.3% |
| Q1 2023 | $50,713,558 | -5.7% | 1,407,537 | +3.4% | 0.02% | -11.8% |
| Q4 2022 | $53,793,794 | +4.8% | 1,361,179 | +6.6% | 0.02% | -5.6% |
| Q3 2022 | $51,322,000 | +4.6% | 1,277,283 | +9.4% | 0.02% | +5.9% |
| Q2 2022 | $49,073,000 | +17.2% | 1,167,285 | +8.6% | 0.02% | +30.8% |
| Q1 2022 | $41,860,000 | +6.3% | 1,074,421 | +8.7% | 0.01% | +8.3% |
| Q4 2021 | $39,375,000 | +15.2% | 988,086 | +4.4% | 0.01% | +9.1% |
| Q3 2021 | $34,192,000 | +213.8% | 946,099 | +255.9% | 0.01% | +175.0% |
| Q2 2021 | $10,897,000 | +1.9% | 265,825 | +8.4% | 0.00% | 0.0% |
| Q1 2021 | $10,693,000 | +18.4% | 245,137 | +35.8% | 0.00% | 0.0% |
| Q4 2020 | $9,035,000 | -0.0% | 180,501 | -16.0% | 0.00% | 0.0% |
| Q3 2020 | $9,039,000 | +15.2% | 214,855 | +32.9% | 0.00% | 0.0% |
| Q2 2020 | $7,849,000 | – | 161,667 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |